Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF. Approved in 2021 based on data from the FIDELIO-DKD and FIGARO-DKD trials, Bayer announced on August 05, 2024 the FINEARTS-HF trial had met its primary endpoint
Under pathological conditions, the excessive accumulation of liver-derived carnitine/acylcarnitine can also trigger a series of adverse events
Oral GLP-1 can be a clinically appropriate choice for the right patient
Because the FDA has approved NAC for some medical uses, it's considered a drug in the United States
For example, patients who take Sermorelin experience more hunger compared to those who use CJC/Ipamorelin
They call this process peptide painting, and it involves GLP-1 receptor agonists